सब दिखाएं

RSV administration error resources: ATAGI advice and clinical guidance

Following reports of RSV administration errors to the Therapeutic Goods Administration (TGA), ऑस्ट्रेलियाई टीकाकरण रजिस्टर (एआईआर) and local vaccine safety surveillance systems, अतगी has issued a statement reiterating appropriate product indications and recommendations.

The ATAGI Statement on Respiratory Syncytial Virus (RSV) immunisation products and prevention of administration errors includes guidance on the correct administration of RSV immunisation products and actions following inadvertent administration of the incorrect product.

Clinical guidance on the actions required following any RSV administration error has also been included in the Australian Immunisation Handbook.

Practices and immunisers should take appropriate steps to prevent errors, particularly in the context of a relatively new immunisation program. In the event of an error, the vaccinee or guardian should be informed via an open disclosure discussion. The error should also be reported to the jurisdiction’s vaccine safety service (SAEFVIC in Victoria).

Further support can be found via MVECs’ eLearning Vaccine Errors: Prevention, management and open disclosure.

द्वारा ऐलिस ब्लैक

National Immunisation Program pneumococcal changes: Prevenar 20

From 1 September 2025, Prevenar 20 will replace Prevenar 13 और Pneumovax 23 on the childhood and adolescent National Immunisation Program (NIP) schedule.

Routine doses are scheduled at 6 weeks, 4 months and 12 months of age, with an additional dose given for higher risk children at 6 months of age or at diagnosis of the at-risk condition. There is no need to recall a person for ‘catch-up’ if they have already completed their full course of pneumococcal vaccination.

Prevenar 20 is a conjugated vaccine that protects against the bacteria स्ट्रैपटोकोकस निमोनिया. In addition to the protection against the 13 serotypes covered in Prevenar 13, Prevenar 20 offers protection against serotypes 8, 10A, 11A, 12F, 15B, 22F, 33F.

There are no changes to the adult schedule at this time.

Read more on the program changes via the NIP Fact sheet
Read more about pneumococcal at एमवीईसी: न्यूमोकोकल

For further information and the opportunity to ask questions, please save the date for MVEC's upcoming webinar CVU mini: Pneumococcal update. (Recording now available exclusively for Education Portal members.)

द्वारा ऐलिस ब्लैक

TGA: Varicella vaccine shortages

Immunisation providers should be aware of current shortages of the monovalent वैरीसेला vaccines in Australia. This shortage in supply impacts both Varilrix and Varivax. There is no impact to government or NIP stock.

For more information, visit the TGA Medicine shortages report database.

द्वारा ऐलिस ब्लैक

In memory of Prof David Isaacs

The MVEC and SAEFVIC teams are deeply saddened by the passing of Prof David Isaacs.

David was not only a well respected paediatric infectious diseases expert, he was also a fierce defender of the rights and wellbeing of children, and a mentor and friend to many. The MVEC team was honoured to have David as a special guest at our 2019 Clinical Vaccinology Update.

His contributions to vaccine policy as member of ATAGI, PBAC and Polio Expert Panel in support of the Global Polio Eradication Initiative leave a lasting legacy.

द्वारा ऐलिस ब्लैक

UQ news: Billion-dollar deal takes UQ vaccine tech to the world

Pharmaceutical company Sanofi has acquired the rights to a unique vaccine technology developed by University of Queensland (UQ) scientists.

The Molecular Clamp platform “streamlines vaccine development across different viral families” according to UQ researchers.

Read more on the UQ website.

द्वारा ऐलिस ब्लैक